Literature DB >> 16616387

Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck.

Vincent Grégoire1, Avraham Eisbruch, Marc Hamoir, Peter Levendag.   

Abstract

BACKGROUND AND
PURPOSE: In 2003, a panel of experts published a set of consensus guidelines regarding the delineation of the neck node levels (Radiother Oncol, 2003; 69: 227-36). These recommendations were applicable for the node-negative and the N1-neck, but were found too restrictive for the node-positive and the post-operative neck. PATIENTS AND METHODS: In this framework, using the previous recommendations as a backbone, new guidelines have been proposed taking into account the specificities of the node-positive and the post-operative neck.
RESULTS: Inclusion of the retrostyloid space cranially and the supra-clavicular fossa caudally is proposed in case of neck nodes (defined radiologically or on the surgical specimen) located in levels II, and IV or Vb, respectively. When extra-capsular rupture is suspected (on imaging) or demonstrated on the pathological specimen, adjacent muscles should also be included in the CTV. For node(s) located at the boundary between contiguous levels (e.g. levels II and Ib), these two levels should be delineated. In the post-operative setting, the entire 'surgical bed' should be included. Last, the retropharyngeal space should be delineated in case of positive neck from pharyngeal tumors.
CONCLUSIONS: The objective of the manuscript is to give a comprehensive description of the new set of guidelines for CTV delineation in the node-positive neck and the post-operative neck, with a complementary atlas of the new anatomical structures to be included.

Entities:  

Mesh:

Year:  2006        PMID: 16616387     DOI: 10.1016/j.radonc.2006.03.009

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  78 in total

Review 1.  Balancing risk and reward in target delineation for highly conformal radiotherapy in head and neck cancer.

Authors:  Avraham Eisbruch; Vincent Gregoire
Journal:  Semin Radiat Oncol       Date:  2009-01       Impact factor: 5.934

Review 2.  Clinical application of intensity-modulated radiotherapy for head and neck cancer.

Authors:  O Ballivy; R Galiana Santamaría; A Lozano Borbalas; F Guedea Edo
Journal:  Clin Transl Oncol       Date:  2008-07       Impact factor: 3.405

3.  Locoregional recurrences after post-operative volumetric modulated arc radiotherapy (VMAT) in oral cavity cancers in a resource constrained setting: experience and lessons learned.

Authors:  S Chakraborty; V M Patil; S Babu; G Muttath; S K Thiagarajan
Journal:  Br J Radiol       Date:  2015-02-03       Impact factor: 3.039

Review 4.  Organ-sparing radiation therapy for head and neck cancer.

Authors:  XiaoShen Wang; ChaoSu Hu; Avraham Eisbruch
Journal:  Nat Rev Clin Oncol       Date:  2011-07-26       Impact factor: 66.675

Review 5.  The evolution of nasopharyngeal carcinoma staging.

Authors:  Rui Guo; Yan-Ping Mao; Ling-Long Tang; Lei Chen; Ying Sun; Jun Ma
Journal:  Br J Radiol       Date:  2019-07-12       Impact factor: 3.039

6.  IMRT and IGRT in head and neck cancer: Have we delivered what we promised?

Authors:  Gupta Tejpal; Agarwal Jaiprakash; Bannerjee Susovan; Sarbani Ghosh-Laskar; Vedang Murthy; Ashwini Budrukkar
Journal:  Indian J Surg Oncol       Date:  2010-11-21

7.  Intensity-modulated radiotherapy vs. parotid-sparing 3D conformal radiotherapy. Effect on outcome and toxicity in locally advanced head and neck cancer.

Authors:  M Lambrecht; D Nevens; S Nuyts
Journal:  Strahlenther Onkol       Date:  2013-01-16       Impact factor: 3.621

8.  Interobserver variation in clinical target volume and organs at risk segmentation in post-parotidectomy radiotherapy: can segmentation protocols help?

Authors:  M Mukesh; R Benson; R Jena; A Hoole; T Roques; C Scrase; C Martin; G A Whitfield; J Gemmill; S Jefferies
Journal:  Br J Radiol       Date:  2012-08       Impact factor: 3.039

9.  Definitive radiochemotherapy of advanced head and neck cancer with carboplatin and paclitaxel : a phase II study.

Authors:  Robert Semrau; Susanne Temming; Simon Florian Preuss; Jens Peter Klubmann; Orlando Guntinas-Lichius; Rolf-Peter Müller
Journal:  Strahlenther Onkol       Date:  2011-09-23       Impact factor: 3.621

10.  Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial.

Authors:  Alexandra D Jensen; Jürgen Krauss; Karin Potthoff; Christian Simon; Anna V Nikoghosyan; Karen Lossner; Jürgen Debus; Marc W Münter
Journal:  Radiat Oncol       Date:  2012-04-02       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.